Icosavax, a Phase 1 biotech developing vaccines for respiratory diseases, announced terms for its IPO on Thursday.The Seattle, WA-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. At the midpoint of the proposed range, IcosavaIPOs Feed


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.